A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment

Conditions

• Idiopathic Pulmonary Fibrosis

Eligibility Criteria

Sex

ALL

Age

40 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• BI 765423 — DRUG
  BI 765423
• Placebo — DRUG
  Placebo to BI 765423

Study Details

This study is open to adults who are at least 40 years old and have idiopathic pulmonary fibrosis (IPF). People can participate in the study if they have a forced vital capacity (FVC) greater than or equal to 45% of the predicted value and fibrosis of 20% or more confirmed by a high-resolution computed tomography (HRCT) scan. The purpose of this study is to find out if a medicine called BI 765423 can improve lung function in people with IPF. The study will compare BI 765423 with a placebo to see if there is a difference in lung capacity after 3 months of treatment and will also look at changes in certain markers related to lung health. Participants are put into two groups randomly, which means by chance. One group receives the study medicine, and the other group receives a placebo. Placebo looks like BI 765423 but does not contain any study medicine. The study medicine is given as an infusion into a vein every four weeks. Participants are in the study for 8-10 months. During the study, participants may continue their regular treatment for IPF. During the study they visit the study site several times for screening, treatment, and follow-up. Doctors regularly test lung function by measuring FVC and take blood samples to measure study endpoints. The results are compared between the two groups to see whether the treatment works. The doctors also check participants' health and take note of any unwanted effects.

Key Dates

Start date

Nov 13, 2025

Status verified

Jun 2026

Primary completion

Apr 28, 2027

Completion

Jun 22, 2027

Study Design

Enrollment

71 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: BI 765423
• Placebo Comparator: Placebo

Primary Outcome Measure

Absolute change from baseline in FVC (mL) at 12 weeks [ Time Frame: Baseline, 12 weeks ]

Central Contacts

• Boehringer Ingelheim
  1-800-243-0127
  [email protected]

Locations (15)

Find similar trials in Birmingham, AL

Related Studies

• Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF)
  Recruiting · University of Pittsburgh · Pittsburgh, Pennsylvania
• Mechanisms of Familial Pulmonary Fibrosis
  Recruiting · Vanderbilt University Medical Center · Nashville, Tennessee
• Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure
  PHASE1/PHASE2 · Recruiting · Paul Szabolcs · Pittsburgh, Pennsylvania
• Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis
  PHASE1 · Recruiting · University of Alabama at Birmingham · Birmingham, Alabama